Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22531792 | 1.00 | BRAF (0.45) | BRAFJAK1BRD4CYP3A4SLC40A1 | |
| SCHEMBL22531802 | 0.87 | JAK1 (0.43) | BRAFJAK1BRD4SLC40A1PTPN11 | |
| SCHEMBL22531663 | 0.85 | JAK1 (0.41) | BRAFJAK1BRD4CYP3A4SLC40A1 | |
| SCHEMBL29588456 | 0.79 | BRAF (0.44) | BRAFBRD4CYP3A4PTPN11 | |
| SCHEMBL22531694 | 0.79 | BRAF (0.44) | BRAFBRD4CYP3A4PTPN11 | |
| SCHEMBL22531789 | 0.78 | CRBN (0.43) | BRAFJAK1BRD4CYP3A4 | |
| SCHEMBL29588449 | 0.78 | CRBN (0.43) | BRAFJAK1BRD4CYP3A4 | |
| SCHEMBL29588880 | 0.76 | CRBN (0.49) | BRAFBRD4CYP3A4ACLY | |
| SCHEMBL22531786 | 0.76 | CRBN (0.49) | BRAFBRD4CYP3A4ACLY | |
| SCHEMBL30925446 | 0.76 | SLC40A1 (0.67) | BRAFSLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368627-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | Peloton Therapeutics, Inc., a fully owned subsidiary of Merck Sharp & Dohme LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20220162193-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | PELOTON THERAPEUTICS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162193-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | RBM39, RBM3, RBM28 | BRAF 1224/4885JAK1 4097/4885BRD4 1330/4885 |
| US-20250368627-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | RBM39, RBM3, RBM28 | BRAF 1224/4885JAK1 4097/4885BRD4 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.